NCT00092040View on ClinicalTrials.gov

A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)

PHASE3CompletedINTERVENTIONAL

Enrollment

936

Participants

Timeline

Start Date

March 18, 2003

Primary Completion Date

October 18, 2004

Study Completion Date

September 28, 2005

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

MK0217, alendronate sodium/Duration of Intervention: 12 mo

DRUG

Comparator: risedronate / Duration of Intervention: 12 mo

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00092040 - A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907) | Biotech Hunter | Biotech Hunter